STOCK TITAN

Volitionrx - VNRX STOCK NEWS

Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.

VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.

Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.

The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.

Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.

Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the results of two large-scale clinical studies demonstrating that its Nu.Q® assays, in conjunction with the Fecal Immunochemical Test (FIT), can significantly enhance the detection of colorectal cancer and advanced adenomas in symptomatic patients, potentially reducing unnecessary colonoscopies by up to 28%. The studies involved 476 symptomatic and 520 asymptomatic patients, showing improved results over traditional FIT methods. Findings will be presented at ASCO GI 2022, emphasizing the importance of early diagnosis in colorectal cancer management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed SAGE Healthcare Private Limited as a non-exclusive licensee and distributor for its Nu.Q® Vet Cancer Screening Test in Singapore. The test launch is slated for Q1 2022, with plans for further expansion across Asia. Volition aims to establish similar agreements globally to enhance accessibility to the Nu.Q® Test. Ongoing negotiations with multinational veterinary companies are progressing, with potential contracts expected soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
-
Rhea-AI Summary

VolitionRx Limited (VNRX) reported its third quarter financial results for 2021, highlighting a cash position of $22.9 million and an average monthly cash burn rate of $1.7 million. The company is in advanced negotiations with three major veterinary firms for licensing agreements and has expanded its intellectual property assets. Despite a net loss of $7.2 million this quarter, increased from $5.6 million in the prior quarter, Volition is optimistic about its Nu.Q® products' potential and upcoming launches. A conference call is scheduled for November 11, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced a conference call on November 11, 2021, at 8:00 a.m. Eastern time to discuss its third quarter 2021 financial results and provide a business update. The call will include updates on ongoing clinical trials and key events from Q3 2021. CEO Cameron Reynolds, along with other executives, will lead the discussion. Investors can access a live audio webcast from their investor relations page. A telephone replay will be available until November 25, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) presented two significant abstracts at the 2021 Veterinary Cancer Society Conference. The first highlights the effectiveness of Nu.Q® in monitoring disease response and progression in cancer-bearing dogs, showing potential for early identification of remission. The second abstract introduces Nu.Q® Capture, an enrichment tool for analyzing circulating nucleosomes in dogs with lymphoma. These advancements pave the way for a second Nu.Q® Vet product launch planned for 2022, reinforcing Volition's commitment to improving cancer diagnostics in veterinary medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) reported strong progress in its second quarter ended June 30, 2021, highlighting a solid balance sheet with $27.9 million in cash. The company has expanded its intellectual property portfolio, added key personnel, and published significant clinical research. Notably, the beta launch of the Nu.Q® Vet platform received high interest for licensing. However, they reported a net loss of $5.6 million for the quarter and continue to face operational challenges due to the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) will host a conference call on August 12, 2021, at 8:00 a.m. Eastern time to discuss its second quarter 2021 financial results and provide a business update. The call will feature insights from key executives, including Cameron Reynolds, CEO, and Terig Hughes, CFO. Topics will include new and ongoing clinical trials and significant events from the second quarter. Interested parties can join via dial-in or access a live audio webcast on the company's investor relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced promising results from its Nu.Q® NETs assay in COVID-19 studies presented at the ISTH Congress 2021. This assay correlates with disease severity, predicting future COVID-19 outcomes and assisting in risk stratification for treatment. The findings suggest potential in monitoring disease progression, particularly in intensive care scenarios. Ongoing large studies on COVID-19, sepsis, and more are expected to yield further data shortly, indicating a strong pipeline for Volition's diagnostic capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced its first-quarter financial results for 2021, reporting approximately $33.1 million in cash, significantly up from $19.4 million at the end of 2020. The company added approximately $20.3 million through stock offerings and secured $4 million in non-dilutive funding. Leadership was strengthened with new executive appointments. The company expanded its intellectual property with 28 patent families and published three clinical papers, demonstrating progress in its Nu.Q® diagnostic platform, particularly in veterinary applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced a conference call scheduled for May 12, 2021, at 8:00 a.m. Eastern time to report its first quarter 2021 financial results. The call will be hosted by CEO Cameron Reynolds and CFO Terig Hughes, discussing new clinical trials and significant milestones. The call will also be available via a live audio webcast on Volition's investor relations website, with a replay option available until May 26, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Stock Data

48.18M
73.27M
23.38%
20.36%
0.61%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON